Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DPYD | Q12882 | 2/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8508879 | 0.80 | KMT2A (0.41) | KDM3BKMT2ATDP1DPYDUBE2N | |
| SCHEMBL13296 | 0.80 | DPYD (0.59) | KMT2ADPYDMEN1 | |
| SCHEMBL23622043 | 0.76 | DPYD (0.64) | KDM3BKMT2ATDP1DPYDUBE2N | |
| SCHEMBL187437 | 0.76 | DPYD (0.64) | KDM3BKMT2ATDP1DPYDMEN1 | |
| SCHEMBL6510854 | 0.75 | DPYD (0.49) | DPYD | |
| SCHEMBL4373860 | 0.73 | DPYD (0.41) | DPYD | |
| Thymine SCHEMBL14695416 | 0.73 | ATAD2 (0.66) | DPYD | |
| Pyrimidine SCHEMBL28139051 | 0.69 | DPYD (0.46) | KMT2ADPYDMEN1 | |
| Pyridine SCHEMBL28177470 | 0.69 | DPYD (0.46) | KMT2ADPYDMEN1 | |
| SCHEMBL29410890 | 0.69 | DPYD (0.37) | DPYD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023039068-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PEPTIDE NUCLEIC ACID INTERMEDIATES | NEUBASE THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | claimed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | claimed |
| EP-3655388-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | Trucode Gene Repair, Inc. (US) | 2020-05-27 | — | — | EP | claimed |
| EP-3601237-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | Trucode Gene Repair, Inc. (US) | 2020-02-05 | — | — | EP | claimed |
| CN-110740994-A | Peptide Nucleic Acid (PNA) monomers with orthogonally protected ester moieties | 特鲁科德基因修复公司 | 2020-01-31 | — | — | CN | claimed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | claimed |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | NEUBASE THERAPEUTICS, INC. | 2018-10-04 | — | — | US | claimed |
| WO-2018175927-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | TRUCODE GENE REPAIR, INC. (US) | 2018-09-27 | — | — | WO | claimed |
| US-9951377-B2 | Methods, kits and compositions pertaining to the suppression of the detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid | APPLIED BIOSYSTEMS, LLC (US) | 2018-04-24 | — | — | US | claimed |
| WO-2005052193-A2 | METHODS FOR DETERMINING THE DEGRADATION STATE OR CONCENTRATION OF NUCLEIC ACIDS | APPLERA CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050123975-A1 | Methods for determining the degradation state or concentration of nucleic acids | APPLERA CORPORATION (US) | 2005-06-09 | — | — | US | claimed |
| JP-2004524032-A | — | — | 2004-08-12 | — | — | JP | claimed |
| US-20040142355-A1 | Methods, compositions and libraries pertaining to PNA dimer and PNA oligomer synthesis | BOSTON PROBES, INC. | 2004-07-22 | — | — | US | claimed |
| US-20040137469-A1 | Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis | BOSTON PROBES, INC. | 2004-07-15 | — | — | US | claimed |
| EP-1412517-A4 | METHODS, KITS AND COMPOSITIONS OF COMBINATION OLIGOMERS | BOSTON PROBES INC (US) | 2004-07-07 | — | — | EP | claimed |
| EP-1412517-A2 | METHODS, KITS AND COMPOSITIONS OF COMBINATION OLIGOMERS | Boston Probes, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2004022578-A2 | METHODS, COMPOSITIONS AND LIBRARIES PERTAINING PNA DIMER AND PNA OLIGOMER SYNTHESIS | APPLERA CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20030077608-A1 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | APPLIED BIOSYSTEMS, LLC | 2003-04-24 | — | — | US | claimed |
| WO-2002072865-A2 | METHODS, KITS AND COMPOSITIONS OF COMBINATION OLIGOMERS | BOSTON PROBES, INC. (US) | 2002-09-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123975-A1 | Methods for determining the degradation state or concentration of nucleic acids | NSUN2, RNGTT, NSUN3 | KDM3B 1619/4885KMT2A 1361/4885TDP1 94/4885 |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | KDM3B 4479/4885KMT2A 1921/4885TDP1 334/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KDM3B 4366/4885KMT2A 2365/4885TDP1 184/4885 |
| US-20030077608-A1 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | APP, CUL4B, IAPP | KDM3B 3925/4885KMT2A 3636/4885TDP1 293/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | KDM3B 4479/4885KMT2A 1921/4885TDP1 334/4885 |
| US-20040137469-A1 | Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis | NCL, RNGTT, SSB | KDM3B 4371/4885KMT2A 3279/4885TDP1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.